Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Orthofix Medical Inc. has received a consensus rating of "Moderate Buy" from analysts, with one sell, one hold, and four buy ratings among six ratings firms.
• The average target price for Orthofix stock is $21.75, reflecting analysts' updates over the past year.
• Institutional investors hold 89.76% of Orthofix Medical's stock, indicating strong confidence from larger investment firms.

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $21.75.

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Barrington Research reiterated an "outperform" rating and set a $17.00 target price on shares of Orthofix Medical in a research note on Thursday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Orthofix Medical in a research note on Saturday.

Institutional Investors Weigh In On Orthofix Medical

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue acquired a new stake in Orthofix Medical during the third quarter worth approximately $30,000. CWM LLC lifted its holdings in Orthofix Medical by 99.0% during the third quarter. CWM LLC now owns 1,920 shares of the medical device company's stock worth $28,000 after acquiring an additional 955 shares during the period. Squarepoint Ops LLC lifted its holdings in Orthofix Medical by 515.6% during the second quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company's stock worth $1,312,000 after acquiring an additional 98,552 shares during the period. State of Wyoming increased its position in Orthofix Medical by 85.7% in the second quarter. State of Wyoming now owns 17,657 shares of the medical device company's stock worth $197,000 after buying an additional 8,150 shares during the last quarter. Finally, Rubric Capital Management LP increased its position in Orthofix Medical by 0.7% in the second quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company's stock worth $41,497,000 after buying an additional 26,769 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company's stock.

Orthofix Medical Stock Performance

Shares of NASDAQ:OFIX opened at $15.97 on Friday. The business has a fifty day moving average of $14.77 and a 200-day moving average of $12.93. The firm has a market cap of $630.66 million, a PE ratio of -5.04 and a beta of 0.89. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $20.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.67.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The firm had revenue of $203.12 million during the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Orthofix Medical will post -2.81 EPS for the current fiscal year.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.